News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AxoGen, Inc. (AXGN) On Preliminary List Of Additions To Russell Microcap® Index



6/16/2014 9:20:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Nerve repair company achieves requirements for inclusion in equity market index

ALACHUA, FL – June 16, 2014 – AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the $1.6 billion US peripheral nerve repair market, announced today that it was included on a preliminary list of additions to the Russell Microcap® Index according to information posted by Russell Investments on June 13, 2014. The final 2014 reconstitution of the Russell Indexes will take place after the market closes on June 27, 2014 and final membership lists will be posted on June 30, 2014, with trading in the reconstituted indexes commencing that same day.

The Russell Microcap® Index measures the performance of the microcap segment of the U.S. equity market and is composed of the 1,000 companies with the smallest market capitalization in the Russell 2000® Index, plus the next smallest 1,000 eligible securities by market cap. Inclusion in the Russell Microcap® Index will remain in place for the ensuing 12-month period. The Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. According to Russell Investments, $4.1 trillion in institutional assets currently are benchmarked to its indexes. The Russell Microcap® Index is completely reconstituted annually to ensure new and growing equities are reflected and companies continue to reflect appropriate capitalization and value characteristics.

About AxoGen, Inc.

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation

Contact:
AxoGen, Inc.
Lee Robert "Bob" Johnston, Jr., Chief Financial Officer
386.462.6856
InvestorRelations@AxoGenInc.com

EVC Group
Michael Polyviou/Robert Jones – Investor Relations
212.850.6020/646.201.5447
mpolyviou@evcgroup.com; bjones@evcgroup.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES